For the quarter ending 2026-03-31, SLNO had $62,920K increase in cash & cash equivalents over the period. $25,940K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 31,378 | 43,358 | 26,013 | -48,481 |
| Depreciation and amortization | 514 | 509 | 502 | 1,006 |
| Accretion of premium/discount on marketable securities | 221 | 1,192 | 371 | 1,954 |
| Non-cash lease expense | 149 | 123 | 120 | 364 |
| Amortization of debt issuance costs | 8 | 9 | 9 | 17 |
| Operating lease liabilities | - | - | -115 | -74 |
| Stock-based compensation expense | 16,056 | 11,471 | 9,998 | 24,377 |
| Accrued clinical trial site costs | - | - | - | 37 |
| Change in fair value of stock warrants | - | 0 | - | - |
| Change in fair value of contingent consideration | 484 | 854 | 614 | 4,068 |
| Other non-cash reconciling items | 28 | 13 | -14 | -16 |
| Accounts receivable | 18,931 | 2,702 | 882 | 24,624 |
| Inventory | 1,831 | 8,020 | 3,916 | 2,095 |
| Prepaid expenses, other current assets and other assets | -780 | 3,451 | 948 | 339 |
| Accounts payable | -2,970 | 4,286 | 1,929 | -2,603 |
| Accrued compensation | -3,954 | 2,429 | 981 | 1,491 |
| Operating lease liabilities | -133 | -308 | - | - |
| Essentialis acquisition milestone payments | 2,954 | - | - | - |
| Other liabilities | 7,633 | 1,162 | 9,543 | 3,434 |
| Net cash provided by (used in) operating activities | 25,980 | 48,704 | 43,454 | -45,360 |
| Purchases of property and equipment | 40 | 58 | 1 | 14 |
| Purchases of marketable securities | 101,268 | 187,840 | 163,172 | 104,764 |
| Maturities of marketable securities | 139,291 | 62,538 | 71,730 | 119,800 |
| Net cash provided by investing activities | 37,983 | -125,360 | -91,443 | 15,022 |
| Proceeds from the sale of common stock, net of issuance costs | - | 0 | 215,721 | - |
| Proceeds from the sale of common stock, common stock warrants and pre-funded stock warrants, net of issuance costs | - | 0 | - | - |
| Proceeds from issuance of debt, net of issuance costs | - | 0 | - | - |
| Payment for repurchase of common stock | 4 | 100,146 | - | - |
| Payment of debt issuance costs | 0 | 0 | 0 | 62 |
| Proceeds from exercise of common stock and pre-funded stock warrants | - | 5,187 | - | - |
| Proceeds from exercise of common stock warrants | -5,187 | - | 0 | 5,187 |
| Proceeds from exercise of stock options | 52 | 954 | 2,255 | 13,993 |
| Tax withholding payments for net share-settled equity awards | 1 | 708 | 0 | 33 |
| Payment of deferred financing costs | - | - | - | 178 |
| Essentialis acquisition milestone payments | 1,090 | - | - | - |
| Net cash provided by (used in) financing activities | -1,043 | -99,900 | 218,154 | 18,907 |
| Net increase (decrease) in cash and cash equivalents | 62,920 | -176,556 | 170,165 | -11,431 |
| Cash and cash equivalents, beginning of period | 70,106 | 246,662 | 87,928 | - |
| Cash and cash equivalents, end of period | 133,026 | 70,106 | 246,662 | - |
SOLENO THERAPEUTICS INC (SLNO)
SOLENO THERAPEUTICS INC (SLNO)